Brief: Elevation Oncology Reports Third Quarter 2022 Financial Results

Elevation Oncology

03/11/2022 11:50

Nov 3 (Reuters) - Elevation Oncology Inc  ELEV.O :
    * ELEVATION ONCOLOGY REPORTS THIRD QUARTER 2022 FINANCIAL
RESULTS
AND HIGHLIGHTS RECENT COMPANY PROGRESS
    * ELEVATION ONCOLOGY INC - ON TRACK TO REPORT ADDITIONAL
INTERIM
SERIBANTUMAB DATA FROM PHASE 2 CRESTONE STUDY IN FIRST HALF OF
2023
    * ELEVATION ONCOLOGY INC - PREPARATIONS ARE UNDERWAY TO
INITIATE A
PHASE 1 CLINICAL TRIAL OF EO-3021 IN US IN 2023
    * ELEVATION - EXPECTS EXISTING CASH, CASH EQUIVALENTS &
MARKETABLE
SECURITIES AS OF SEPT 30, 2022, SUFFICIENT TO FUND CURRENT
OPERATIONS INTO 2024
    * ELEVATION ONCOLOGY INC - NET LOSS FOR THE THIRD QUARTER
2022 WAS
$38.8 MILLION, COMPARED TO $12.3 MILLION FOR THE THIRD QUARTER
2021

Source text for Eikon:  ID:nPn1qD3fLa 
Further company coverage:  ELEV.O 
 ((Reuters.Briefs@thomsonreuters.com;))